Sign in
Taking people in United StatesPhase 1/2

Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)

Key facts

Who runs it
Denali Therapeutics Inc.
Where
Chapel Hill, Houston, Iowa City, and Oakland, United StatesSee the 4 sites
Trial code
Status
Recruiting
Phase
Phase 1/2
People taking part
30 people, planned
Started
7 Dec 2023
Expected to end
Jul 2032
Type of study
Interventional, 6 groups
Treatments tested
  • DNL126
  • Prophylactic immunomodulatory therapy
Record updated
2 November 2026

Who can take part

Age
0 years to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Confirmed diagnosis of MPS IIIA
  • For Cohorts A2 and C1: No more than 1 participant may have predictors of a slow-progressing phenotype
  • For Cohort A3: Approximately 2 participants will have predictors of the slow-progressing phenotype
  • For Cohort B1: Have a severe phenotype based on having at least one of the following:; An older sibling with the same genotype and severe MPS IIIA, in the opinion of the investigator; A definitive genotype indicative of severe MPS IIIA, in the opinion of the investigator; Clinical symptoms of MPS IIIA prior to 28 months of age that, in the opinion of the investigator, are indicative of severe MPS IIIA
  • For Cohort B2: Are an older sibling of a participant in Cohort B1 (who has already been confirmed to be eligible for dosing) with MPS IIIA, the same causative genotype, and who has severe MPS IIIA in the opinion of the investigator
  • For Cohort C1: Have up-to-date age-specific vaccination status, including SARS-CoV-2 (COVID-19) vaccines, according to country-specific guidelines at the time of the screening visit

Who cannot take part

  • Have used any CNS-targeted MPS IIIA enzyme replacement therapy (ERT) (eg, intrathecal SGSH or TfR-mediated SGSH delivery to CNS) within 3 months before Day 1
  • Have a prior history of hematopoietic stem cell transplantation
  • Have a prior history of gene therapy
  • Have clinically significant thrombocytopenia, other clinically significant coagulation abnormality, significant active bleeding, or require treatment with an anticoagulant or more than two antiplatelet agents
  • Have unstable or poorly controlled medical condition(s) or significant medical or psychological comorbidity or comorbidities that, in the opinion of the investigator, would interfere with safe participation in the trial or interpretation of study assessments
  • Have a documented likely pathogenic mutation sufficient to cause disease (eg, taking into account zygosity) of other genes that are known to be associated with developmental delay, seizures, or other significant CNS disorders
  • Have a clinically significant history of stroke, status epilepticus, head trauma with loss of consciousness, or any clinically significant CNS disease that is not MPS IIIA-related within 3 months of screening
  • Have any clinically significant CNS trauma or disorder, including severe untreated intracranial hypertension or brain surgery, that, in the opinion of the investigator, may interfere with assessment of study endpoints or make participation in the study unsafe
  • Have lost the ability to walk independently, in the opinion of the investigator
  • Are unable to take the majority of nutrition via mouth, in the opinion of the investigator
  • For Cohort B only: Are homozygous or compound heterozygous for the N-sulfoglucosamine sulfohydrolase (SGSH) S298P mutation or any other mutation known to be associated with slow-progressing phenotype
  • Have used genistein or anakinra within 7 days of screening or intended use of genistein or anakinra during the study
  • Contraindication for lumbar punctures
  • Contraindication for MRI scan
  • Have had a ventriculoperitoneal (VP) shunt placed or a clinically significant VP shunt malfunction within 30 days of screening

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 0 and 18 years old?

This trial is currently available in United States.

  • University of North Carolina at Chapel HillChapel Hill, United StatesContact: Lindsay TorriceTaking people
  • Baylor College of Medicine and Texas Children's HospitalHouston, United StatesContact: Varsha YallamanchiTaking people
  • University of Iowa Stead Family Children's HospitalIowa City, United StatesContact: Lauren VanOpdorpTaking people
  • UCSF Benioff Children's Hospital OaklandOakland, United StatesContact: Ivy Lee HungTaking people

About the trial

What the trial wants to find out

This is a multicenter, open-label, Phase 1/2 study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of DNL126 in participants with Sanfilippo syndrome Type A (MPS IIIA). In Part 1, the core study period is 25 weeks (approximately 6 months); followed by an open-label extension (OLE), which extends through Week 97 (approximately 18 months); and a long-term extension (LTE), which extends through Week 241 (Year 5). In Part 2, the core study period is 25 weeks in duration followed by an OLE, which extends through Week 49, and an LTE, which extends through Week 241 (Year 5). Participants with MPS IIIA will be enrolled in three planned cohorts, and additional participants with MPS IIIA may be enrolled in three optional cohorts.

Read full original descriptionShow less

The study will enroll up to approximately 30 participants in total: 26 participants in Part 1 (Cohorts A1, A2, A3, B1, and B2 - not enrolling) and 4 participants in Part 2 (Cohort C1 - actively enrolling).

The 6 groups in the trial

  • Cohort A1Treatment being tested

    Participants with MPS IIIA

    Treatment: DNL126

  • Cohort A2Treatment being tested

    Participants with MPS IIIA

    Treatment: DNL126

  • Cohort A3Treatment being tested

    Participants with MPS IIIA

    Treatment: DNL126

  • Cohort B1Treatment being tested

    Participants with MPS IIIA

    Treatment: DNL126

  • Cohort B2Treatment being tested

    Participants with MPS IIIA

    Treatment: DNL126

  • Cohort C1Treatment being tested

    Participants with MPS IIIA

    Treatment: DNL126 and Prophylactic immunomodulatory therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
Criteria questions
Built from NCT06181136, who can take part
Record updated
2 November 2026